Back to Journals » Substance Abuse and Rehabilitation » Volume 6

The pharmacology of neurokinin receptors in addiction: prospects for therapy

Authors Sandweiss A, Vanderah T

Received 25 June 2015

Accepted for publication 23 July 2015

Published 7 September 2015 Volume 2015:6 Pages 93—102


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Li-Tzy Wu

Video abstract presented by Alexander J Sandweiss and Todd W Vanderah.

Views: 1093

Alexander J Sandweiss, Todd W Vanderah

Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA

Addiction is a chronic disorder in which consumption of a substance or a habitual behavior becomes compulsive and often recurrent, despite adverse consequences. Substance p (SP) is an undecapeptide and was the first neuropeptide of the neurokinin family to be discovered. The subsequent decades of research after its discovery implicated SP and its neurokinin relatives as neurotransmitters involved in the modulation of the reward pathway. Here, we review the neurokinin literature, giving a brief historical perspective of neurokinin pharmacology, localization in various brain regions involved in addictive behaviors, and the functional aspects of neurokinin pharmacology in relation to reward in preclinical models of addiction that have shaped the rational drug design of neurokinin antagonists that could translate into human research. Finally, we will cover the clinical investigations using neurokinin antagonists and discuss their potential as a therapy for drug abuse.

Keywords: reward, substance p, alcohol, morphine, cocaine, dopamine

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]